2024-04-05-accounts

CHARITY COMMISSIO FOR ENGLAND AND WALE Cura Myotonl¢ Dystrophy UK¢harlty I¢DMI 1191217 Receipts and payments accounts CC16a Forthe pertod from 06104r2023 05104r2024 To Section A Receipts and payments Unrestricted funds Restricted lund$ Endowment Total funds Last year tp th• nur•￿£ th• nMr••t£ to th• Tr•ar••t£ to lh• n••r••t£ A1 Receipts Don3lw) GfftAid Comtnun Ev9nts Rgfvnd5 SponsorshipslGranls 14,957 1706 288 28.$79 5.009 23.957 3.706 31079 ub totsl{Grtiss Fncome for AR) 51A30 11$00 30 A2 As$8t and investment sales, Ise8 table). Sub total 51.$30 12.590 Futhdrè15illg & Cornmunity Evahts AdmiTr￿tra￿￿n & Runni Paypal 8 JusiGwin Fe8a Rwarth GraDts 31,883 16215 89fj 16.04 31,60J 16215 96 16,040 Advertisng & Pmoutsnai Mer¢hand¢e 4173 2Z5 4.t73 9325 ProfessMg1 Fo09 Sub total 78232 78232 A4 Asset and investment urcha5es, see table Sub total 78232 78232 Net of recelpts/(payments) AS Translers between fiJnd$ A6 Cash funds last year end Cash funds thls ygar and 24701 12.5tKI 14201 34.734 4033 34,734 20,533 11500 CC)X R1 ￿tOunts Issi 02107r2024

Section B Statement of assets and liabilities at the end of the period Unrestricted funds Restrfctsd funds End0vM￿NI funds D￿rn$t£ Calejaries tonur•st£ B1 Cash funds 8arth ACM￿1 12.50• Total cash funds 8.033 12.sfjo 11 OK UnY08frfd8d funds to nearest£ Roslrictsd funds tonearestt fvnds ton•arnst£ Deta'.l$ FundtOwhi¢h Deta.-Is •¥¢ loptirykit) eun•Thtvalu• rAll•whi -Currnrtwlu Details B4 Assets retained fr>r the charltys own use Fundtowhlch Amount du• Von al B5 Llabllttles Swed tyLme or MY>trLts4)7 behaf of 811 the LfLL8tee¥ S¥Jnatyre Pmt Name Date of CCXX R2 t￿￿u￿LS ISSI OW07r2024

CHARITY COMMISSION FOR ENGLANO AND WALES Independent examiner's report on the accounts Section A Independent Examiner's Report Report to the trustees Cure Myolonic Dystrophy UK Charlly {CDMI On accounts for the year ended 0510412024 Charity no (if any) 1191217 Set out on pages 1&2 I report lo the Iruslees on my examination of the acc4)unts of the above charity for the year ended 0510412024. R¢$pon$ibilrt10$ and basis of report As the charitys Iruslfjes, you are respKsnsibl8 forthe preparation of the accounts in accordance with the requirements of the Charities Act 2011. I report In r8SPeCt of my examinatlon of the Trust's accounts carri8d out under section 145 of the 2011 Act and in carrying out my examination. I have followed all the applicable Directions given by the Charity Commission under section 145{5}Ibl of the Act. Independent examiner's statement l.have cx)mpleled my examination. I confim that no m8leri81"matters have comè to my 2ttp.ntit)n in (x)nneetion with thp Éx2minAtion whieth gives me ause to believe that in. any malerial respect.. the accounting records were not kept in accordance with section 130 of the Charities Act.. or the accounts did not accord with the accounting records,. or the accounts did not comply with the applicable requirements conceming the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'lnJe and fairf view which is not a matter considered as part of an independent examination. I have no concerns and have ￿me across no other matters in oonnection with the ex2min2tion lo which attention should be drawn in this report in order lo e able a proper understanding of the accoijnts to be reached. Slgned: Date: 0110712024 Name: Rebecca Rouse TIAS BSR Accountancy Relevant professional qualification{sl or body Ilf any): Chartered Institute of Management Accountants {CIMAI CGMA.ACMA.MIP Address: 15 Crakedale Road

Winterton ON15 guT Section B Disclosure Only cornplele if the examiner needs lo highlight material matters of concern {see CC32, Independent examination of charity accounts- directs'ons and guidance for examiners). Give here brief details of any items that the examiner wishes to disclose.

Cure Myotonic Dystrophy UK Charity (CDM)

(CIO)

REPORT OF THE TRUSTEES: 6[th] April 2023 to 5[th] April 2024

The Trustees present their report together with the financial statements of the Charity for the year ended 5[th] April 2024.

Reference and Administrative Details:

Charity Number: 1191217

Registered Address: c/o Riverside View, Station Rd, Whitton, North Lincs, DN15 9LR

Directors and Trustees:

The currently registered Trustees are:

Emma-Jayne Ashley, Peter Ashley (Chair), Stephen Uncles (all sitting as first trustees). Liam Garwood and Tamsyn Tait (as of 4[th] Jan 2023). Dr Wendy Greenwood (as of 14[th] Dec 2023)

Retired Trustee:

Dr Alison Kay (Sept 2020 to January 2024)

There must be at least three (3) charity trustees. If the number falls below this minimum, the remaining trustee or trustees may act only to call a meeting of the charity trustees or appoint a new charity trustee. Apart from the first charity trustees, every trustee must be appointed for a term of three years by a resolution passed at a properly convened meeting of the charity trustees.

Objectives, Activities, Achievements and Performance:

The objectives of the CIO are:

To preserve and protect good health among, and relieve the needs of, people living with Myotonic Dystrophy, their families and carers, in particular but not exclusively by:

(a) providing information, help and support to such people and their families and carers; (b) making financial donations to support organisations and individuals carrying out research into Myotonic Dystrophy, the useful results of which will be published for public benefit; and (c) raising awareness of Myotonic Dystrophy within the general public, medical and scientific communities.

Raising funds is always high on our priority list. Financial income for this period came from donations and fundraising, the community, sponsorships, grants, and donations from CureDM Ventures CIC.

The Board of Trustees have regular updates/meetings, and an AGM (which is the main source of future Charity planning).

Services were maintained in the following areas:

In person events, consultations, and conferences. Discussions between all stakeholders were held in person, via email and online resources, and via continued utilisation of virtual meetings. For the period April 2023-2024:

Research

• Produced and published CureDM Medication Snapshot – a view of research currently ongoing for Myotonic Dystrophy on a global scale. Updated regularly and

shared with all stakeholders to keep the community up to date with the fast-paced movement of current research.

• Co-Authored guidelines and paper in the British Medical Journal for advancing Palliative and End of Life provision within the DM community.

• Agreed to an increase in grant funding to the UK DM Patient Registry, facilitating access to research and current and upcoming clinical trials for the DM community.

• Steering committee member for the UK Myotonic Dystrophy Patient registry.

• Co-funded UK Natural history study into Adults with Congenital Myotonic Dystrophy – CARE-CDM

• Invited specialists, funded and organised attendance for a number of UK Clinicians to attend the International Myotonic Dystrophy Consortium in Nijmegen (April 2024, planning throughout this financial year).

• Attended international conference as Patient Representatives on TREAT-NMD (TGDOC) Myotonic Dystrophy sub-group – worldwide group representing DM patients in research and patient registry collaboration.

• Updated and re-circulated UK Charity community questionnaire to enable an up-todate vision on DM in the UK.

• Submitted CureDM community research abstract to the International Myotonic Dystrophy Consortium (IDMC), worldwide scientific conference, to be held in 2024 in Nijmegen.

• Co-Authored research posters which were presented at worldwide scientific conferences.

• Supported and advised as DM specialist patient representatives on upcoming awareness videos to be released UK wide in 2025.

• Founding members of Euro-DyMA, an international collaboration of European DM support groups. Euro-DyMA meet regularly online and in person to facilitate research and to define and meet the un-met needs of the DM Community.

• Social Task Force Lead: working with European support groups to produce a research paper on the support and events provided by different organisations within Euro-DyMA.

• Took part in the Euro-DyMA Scientific Advisory Board meeting, ‘Pharma Day’ and AGM.

• Consulted on potential upcoming new worldwide trials, studies and natural history studies for DM1 and CDM. Regular meetings and member of patient representative committees.

• Patient representative for the ILAP application process within MHRA, SMC, AWMSG and NICE.

• Continued to advise on DM relevant study protocol/design as patient representatives on numerous ongoing research projects, including direct meetings with organisations and companies working towards clinical trials for potential new treatments in the UK, and DM natural history studies. Vital to find treatments and therapies for those living with Myotonic Dystrophy.

• Using our Subject Matter expertise in Myotonic Dystrophy to provide input, advice and support to wider Neuromuscular committees and panels.

• Patient representatives for upcoming potential research studies and clinical trials, advising on the complexity of DM/CDM.

• Collaborated with clinicians and researchers to produce disease specific guidelines and advice. Notably Palliative and End of Life Care for DM1.

• Attended and presented at carefully selected worldwide scientific, medical, and clinical conferences (online and in person).

• Ongoing European Patient Advocacy Group representative on the European Reference Network (ERN) for neuromuscular diseases.

• Chair provides representation on the MDUK Lay Research Panel as DM patient expert.

• Ongoing representation as DM patient expert in the SIMPATHIC drug repurposing project.

Awareness:

• Joint founders of the INTERNATIONAL MYOTONIC DYSTROPHY AWARENESS DAY on Sept 15[th] each year.

• Over 40 UK venues and landmarks lit up green to support the CureDM Charity and Awareness Day.

• Continued to promote the awareness day and collaboration throughout the year.

• Member of steering committee for the DM Global Alliance.

• Bi-monthly Global Alliance (online) meetings with worldwide support groups and organisations. Global collaboration to raise awareness and bringing all communities, scientific, research, patients, and pharma, together.

• Produced Charity videos raising awareness of the condition and the work we do, celebrating the community, distributed through social media and on the Charity YouTube page.

• Supported schools/families in providing student education and raising DM awareness for Rare Disease Day 2024. Video can be seen here: https://youtu.be/cKEWm7AJcrU?si=oWQShCkCnAnKb4Tl

• Provided information for university education conference on DM for Rare Diseases for students and clinicians, for Rare Disease Day 2024.

• Attended and held information stall at the Myotonic Dystrophy Foundation annual conference in Washington, USA. Presented information and posters on UK Charity and support. Met with many families living with DM and made worldwide connections.

• Supported worldwide awareness of DM by joining the MDF in advocating for funding for research at Capitol Hill, taking part in meetings with senators and giving the global experience of families living with rare diseases.

• ‘Could it be Myotonic Dystrophy’ posters dissemination to settings where patients may be seen. These are now used worldwide.

• Began work on new CureDM website, providing accurate, DM specific, information and advice.

• Active social media pages include public Charity pages and dedicated private peer support pages, allowing patients and families with DM to connect in private.

• Expanded LinkedIn presence and established a CureDM page, increased network of clinicians, researchers and organisations with an interest in DM.

• Moderated and supported worldwide social media pages for DM1, DM2 and CDM.

• Advocated for families with DM in charitable, social, and medical settings.

• Attended several face-to-face and online medical, research and support conferences and meetings. Including World Orphan Drug Congress, MDSG, MDUK, MDF, MDA, Genetic Alliance, Eurordis, Euro-Dyma, World Muscle Society (WMS,) European Reference Network (ERN), Treat-NMD, and other rare disease communities.

• Presented at some of the above conferences and manned CureDM information stands.

• Co-authored, submitted and were accepted for a number of abstracts for the IDMC in April 2024, showing international collaboration and raising awareness of DM in the UK, including the work we do with other worldwide support groups, Pharma and within the Charity.

• Raised the profile of Myotonic Dystrophy in Rare disease, Neuromuscular, Pharma and Muscular Dystrophy focused collaborations.

Support:

• Planned, funded and organised the annual Families Day event in July 2023. A full activity weekend at The Calvert Trust. Video to event can be seen here:

• https://youtu.be/8YsPHdSePXc?si=1ubcE3w5-SowJ1Bk

• The event was fully funded by the Charity and catered to 20 families, filling the venue with 67 attendees. Participants included people from all over the UK, living with CDM, DM1 and DM2.

• Held a mini conference at the family’s weekend, provided 1:1 support and information materials.

• Facilitated group event at Disney on Ice in Dec 2023, including a group ‘after party’ gathering with food and activities after the show. We are proud to have provided this event free of charge to 50 people (13 families) living with Myotonic Dystrophy.

• Planned and organised community event at The Deep – taking place in next accounting period (May 2024).

• Funded and successfully supported application of a number of disability cards for the community – allowing them to access benefits outside of the Charity.

• Delivered support, advice, and assistance virtually and in person to the Myotonic Dystrophy community, dealing with the queries or passing them on to an appropriate person or organisation.

• Supported individuals and families with day to day, benefits, healthcare, and quality of life concerns and applications.

• Successfully supported community members in applying for genetic testing, disability benefits and home adaptions.

• Continued to provide ‘Miles’ mascots to children with CDM to promote friendship and support.

• Supporting community members by providing information and advice to enable them to advocate for themselves and loved ones in medical situations.

• Supported families dealing with the devastating effects of the condition, including during bereavement of loved ones.

• Initiated monitoring survey within the community, to identify and improve community satisfaction of services provided.

Fundraising:

• Fundraising events included online campaigns and personal fundraisers/donations.

• Grants and sponsorships were received to support conference attendance, admin support and the running costs of the charity, enabling us to use personal donations for community support and facilitating research (ringfenced if specified).

• Successfully received sponsorship to build on community events, enabling the Charity to offer more provision to a wider audience.

• We continued to receive generous donations from people fundraising on our behalf.

• • In memory donations received.

• CureDM Trustees organised and fundraised as a team for the Dundee KiltWalk – meeting with families in Scotland affected by Myotonic Dystrophy.

• Organised and facilitated a team of 13 runners for Great North Run 2023, raising over £7500. Supported by Charity trustees and volunteers during the event.

News and information:

The charity facilitates a private social media group, and a public charity page on Facebook. Also utilising Twitter, LinkedIn, and Instagram accounts. CureDM have a YouTube page to share community videos and charity presentations. These are platforms for sharing articles, peer support, sharing experiences and ideas. Information is shared on research progress and other matters impacting families of disabled children and adults. There is also a website used to keep families up to date with news and events.

The 2023/2024 Impact Report is attached to this Trustee report.

Stakeholders:

• Charity stakeholders are those living with Myotonic Dystrophy, their families and caregivers, those involved in running the Charity, volunteers and those fundraising or raising awareness, the clinicians, researchers and drug developers that engage with and benefit from our work.

• Support, events, and fundraising opportunities are proposed and discussed by stakeholders. Consultations take place regularly in meetings with families, during business meetings and conferences and online via e-mail, the Trustee messenger group, and social media.

• Future peer support get-togethers, activities, meet up plans, venues, dates, and itineraries are planned around consultation with the potential users themselves. Plans are made to include as many people as possible, whilst making efforts to reduce attendee bias and ensure those who have not been able to attend previously are accommodated.

• Day-to-day decisions are made with consultation between trustees, volunteers, and community members as required.

• Strategic or significant financial decisions, such as activities or proposals for research funding, are made following consultation with all trustees, who all have significant experience (personal and professional) knowledge and experience of the conditions, support for others, charitable work, and fundraising.

• Research/Grant funding requests are approved following consultation with the trustees to determine the most appropriate use of funds.

Events:

The charity endeavours to facilitate social events where families can enjoy a relaxed atmosphere whilst sharing their experiences. Events are aimed to facilitate peer support, family memories, forming peer friendships, and encourage the sharing of knowledge to improve day to day quality of life. Events include education to support the community and enable them to advocate for themselves, whilst keeping all stakeholders updated on upcoming advances in healthcare and potential treatments.

Review of Public Benefit:

In setting out the objectives and planning activities, the Trustees have carefully considered the Charity Commission’s general guidance on public benefit. Face to face events were reinstated with provision in place to keep community members as safe as possible after the COVID-19 pandemic. Whilst Covid-19 is mostly managed in day-to-day life, the DM community is vulnerable to this and other respiratory infections, so careful planning is undertaken at all stages.

Future:

CureDM continually strives to expand services to meet growing demand, in a planned and financially prudent way, ensuring all projects stand on a sound financial footing and that the Charity moves forward and grows, but does so responsibly.

Income/Expenditure:

The restrictions necessitated by the Covid-19 pandemic and the vulnerability of the community/families caused a delay in planned social/peer support activities (days out, holidays etc.), normally at the core of the Charity’s work. Careful planning allowed these events to begin again in 20223, showing as an increase in expenditure for this financial period.

It is the belief of the Charity that funds should be used to fulfil the charitable aims as available, and not to accrue a large unused credit which could otherwise be used to benefit the community we serve.

Investment powers and policy:

The CIO has power to do anything which is calculated to further its Objects or is conducive or incidental to doing so, as laid out in the Constitution.

Reserves policy:

The state of the economy means sufficient reserves may need be held to ensure the future running of the charity. There is no policy to date in place dictating reserve amounts. The Trustees carefully monitor the finances throughout the accounting year to ensure adequate funding is available for continuation of services and financial obligations.

Structure, Governance and Management Governing Document:

Cure Myotonic Dystrophy UK Charity (CDM) is a registered charity (charity number 1191217), which achieved registered charity status on 9 September 2020.

The CIO is governed by Constitution of Charitable Incorporated Organisation (Foundation Structure).

The CIO is registered with the Fundraising Regulator.

Appointment of Trustees:

New Trustees are appointed by current board of Trustees at the Annual General Meeting, in accordance with the Charity’s Constitution. No external bodies have the right to appoint Trustees.

Trustee induction and training:

New Trustees are introduced to the operations of the organisation and are given information on the responsibilities of being a Trustee as well as copies of the Constitution. Training is provided to Trustee’s as required.

The board of Trustees meet regularly and administer the CIO. The charity has no employees. The Trustees are responsible for all decisions.

Trustees’ responsibilities require preparation of financial statements that give a true and fair view of the state of affairs of the CIO, at the end of the financial year, and of its surplus or deficit for the financial year.

In doing so the Trustees are required to:

• select suitable accounting policies and then apply them consistently

• observe the methods and principles in the Charities SORP (statement of recommended practice)

• make judgements and estimates that are reasonable and prudent

• state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements

• prepare the financial statements on the going concern basis.

The Trustees are responsible for maintaining accounting records which disclose with reasonable accuracy at any time the financial position of the CIO. The Trustees are also responsible for safeguarding the assets of the Charity, taking reasonable steps for the prevention and detection of fraud and other irregularities.

Signed by two trustees on behalf of all trustees:

Trustee 1

Name and date: Emma-Jayne Ashley 19/07/2024

Trustee 2

Name and date: Stephen Uncles 19/07/2024

Aprfl'23f24 DM Cure DM Support V Awareness V Research Cure Myotonic Dystrophy UK Charity 2023/24 Snapshot - What We Got Up To This Year! CureDM is a very active registered Charity with a mighty community of famiIies, caregivers, loved ones and amazing individuaIs. We exist to support everyone affected by Myotonic Dystrophy (DMI & DM2). Thanks to OUT amazing donors, this year our income incTeased again by over 20010, enabling us to grow our activities and provide: V more Fun & AdventUTOUS Events more Personal Support V more Expertise to Progress New Treatments V more Care Guidelines & Research Posters V more Awareness of Myotonic Dystrophy The Trustees (and MiIes) would like to give a BIG tk £ qo.. toe whose hard work, donations and encouragement make it all possible! 13V ryone O Cure Myotonic Dystrophy VK Charity www.cU￿dm.(O.uk Reg.No.l 191217 lsteyed NDRAISING EGULATOR

vents & S Calvert Trust ort April'23f24 ew8rl- CureDM hired the whole of the Calvert Trust in the beautiful English Lake District for 67 people - 20 families. videos on 4 days of making friends, upliftin& emotional, challenging and rewarding activities. information, support, awards, fun and dancing! None of us will ever forset! coL4ibof a4Xyk H&ksfILL Disney On Ice Back by popular demand CureDM V151ted Disney on Ice! This year over 50 people- 13 families conversed on Birmingham for a dazzling show followed by food and a party. 've all had tirne5 of feeling isolated when livins day to day with DM. This year we expanded our support, offering safe places to connect. emorable community event5 connect people who understand how you feel. Our uently updated Facebook page and Messenger are our main points of contact and s of information. They are free. easy to access. and the fastest way to stay in touch. ryrjoo in CureDM have a profile on X (Twitter), which is great for connecting with researchers and clinicians. In 2023 we launched on Instasram and we have a YouTube page with community videos! ate Facebook group Cure My(?t(?nic iy UK - l'eer 5upp()rt and events is the place fo chat. news, discussion. and to ask questio of the community or to be signposted to further Ip. Iys moderated by the Charity Trustee o ensure the hundreds of member5 can get, or , SUPPOrt in a safe environrnent that can't be n by the wider publAc. Join up ay using the link on our FB page. Throughout the year we've en planning and Iding a new. mo up-to-date. infornLIti . and easier to navigat eb site for ch in 20241 Pfiii't'TYITfl)ai'ity NlthinBadAYe[encewptopltliw￿wlth M)oronic We invest a lot of time in e-mail threads with community members. doctors and researchers. A message to curL'Llmu•outlook.com will be replied to as soon as possible by the best person for your query. Page 2

Fundraising Aprll'23f24. We would like to thank EVERYONE for eaeh and every penny you raise, we simply wouldn't be here to advocate for this community without your incredible generosity and support! Every donation goe5 to Providing Support, Raising Awareness and Facilitating Research for the UK DM commurrity. TFL4NK IOU,. TwmCureDM Of course. huge thanks for the grants and sponsorships! These fund5 allow us to organise bigger and better events and to be at the critical This year we claimed £3,706 in conferences to keep up Gift Aid! UK tax payer? Tick the to date, to advocate and box! _ it makes a real drfference! raise the profile of DM. If you can help with fundraisin& holdins an event. gaining grants or sponsorships, or in any way at all. please contact us. None of this work can happen without our generous supporters. £7451.43 s5￿7￿1 Ih4n15to.. Uy¢yFADty.i¢y Awareness THANK YOU! How can we all hel ? Awareness in healthcare 15 everything. It mean5 more people being diasnosed faster getting the care we need. and easier access to more treatments! Our work this year included: v founding membership of the new Global Alliance steerin8 committee for International DM Awareness Day- 15th September (CureDM jointl.yfiiundL,d da! uihicli noiv illclude the alliancc ofotyer 50 orgau7.qfilion.% arouud t17e worldlj W increasing work with UK & European neuromuscular & rare disease nehvorks v developing our LinkedIn network to raise awareness in researchersi pharmaceutical companies & clinicians v stands & attendance at bigger, key scientific conferences v lobbying Senators & Representatives on Capitol Hill with the MDF for awareness & more research fundins to benefit the worldwide DM community workins on rnore Care Guidelines v creatin8 research posters for specialist conferences producing videos, published via social media & our YouTube pase- www.youtLilie.com/CCureDMCliarit}' O Cure Myotonic Dystrophy UK Cliérily www.curedm.co.uk Reg.No.I 191217 <pl EURO.DYMA "'1 Refere￿ URORDIS ,X• Shar TRÉA MD

Facilitating Research Ap￿1.23￿24 This year we increased our engagement with those undertaking new research into treatments, with ¢linAciang increasins knowledse of DM to improve clAnical and social care, and with or8anisations developing much-needed registries. This included: vpdating and circulating the CureDM Community Survey to show the patient peTSpective eo-authorin8 the Palliative and End of Life provision {PEoLCI in DM creatins and co-authorins 8 posters for the IDMC conference in April '24 increasing UK Patient Regisiry funding and encouraging better communication with patients being patient representatives at the TREAT-NMD TGDOC registry collaboration conference co-funding CARE-CDM. the UK natural history study for Adults living with Congenital DM v helping to develop an upcoming international study of Children with Congenital DM being patient representatives in the large European SIMPATHIC drug repurposing project completing the first Euro-DyMA Social Task Force projects on community engagement and unEnet wcial needs For the first time there is real hope of systemic treatments for Myotonit Dystrophy! CureDM are in touch with all companies that are developin8 clinical trials, from informal meetings to in-depth workshops & meetings with the MHRA & other regulators. -.from investigating We are also reaching out to those promisins idea5 in labs, to clinical trials bein8 earlier in development to encoura8e them to consider the evaluated in people. patient perspective as soon as This year saw the first gerke possible. therapy trial in the UKr If you are interested in learnins (Info. tts ofMrtr¢li 21)24) Pletsse contft¢l us if.you iuould ITke Fnory infvrmnÈion. more about trialsi please contact us for more infonnation. In 2013 we created a comprehensive horizon Scan of potential new Ireatments bein8 developed around the world... rorw'j Meet the CureDM Team l our Trustees have families affected by Myotonic Dystrophy. Each has a unique and varied personal journey 0£ living with DM and diverse profe55ional and wider life experience. Stephen Urtcles Trublee Dad to Matthew & husbanLI lo Paul ICDM & DMII Lia￿ Garwood 'I'rustee Dad to Louie, husb￿7nd t(i Baylev ICDM & DMII ICDM & DMII A warni welcome to Wendy. -1 t71Ji drlixlitsd t(1 be jiyilliiix tlic Curv DM b(M7rdiTrf frTU.%lce s¢Teiih4t uwrkiN% TFT cli71i¢nl develoiJ7v•ilfiirft mre di.w.¥fvH%ed ¥k¢iTrd Greenwood, PhD Trustee Mutn & Wife Follnd Mum SteLI Peter Ashley TTUSt¥e & Chair Dad lo Drega Tam5yn Tait Trustee um lo Daisv ICDMI Thi5 yeor Dr. Alison Koy sleppe doiufr7 ffs Tru.%tve lofvcu.% 011 17er fainiliy ond tiportunitic.q. Ali hos beeii nii integrttl prtrfr of tlie cliority frojji tlie onset 115 ￿foll￿dI}l8 iiiÉrrTbfr ec4r4.4¢ n1¥h[4sF￿[1d1Tts￿ DMI l see thc cli&lleiixe.q hcfvcr.% due to the of tlie h￿rd ¢Tndhgr Tvi.%epfr.4pechve di.$￿.¥ Im A dfj.¥ to drty kn*j%. We Jre cttrreiitl¥ <eeiii% rt Tarid ￿1011111()rt irf was alw4T.ys valued. We uiish17er all the dEvglupine￿l of Iligrfipiesfvrknili DMI lliTIl DM2. My li￿sbAnd tITrcc yoiipig soils, I'iii Ii(wfvlfvr us, ftrTdfor tlie t11014bands uf the very best and liope see her at fftTiiilie% like H< tliftt tlie itexlfew wors utill brinx trcdtiiienls willl the OIIE of our ¢oiNiniinitry rtyenEs soou. voleiitiRlfvrsubslAtilirtl bettgfii lo Ilje coiiiiiiuntty. Learn more about the team by visitins our websÉte- www.curedm.co.uk Luie Dystrupliy UKLnoKily riey.iyu. 11912 li IC.DM & DMI) Page4